Assessing therapeutic potential for a disease signature requires connecting biology to actionable interventions.
Teams must explore thousands of candidate compounds, understand how each drug could impact the dysregulated signature, and balance mechanistic relevance with safety considerations.
Doing this rigorously across programs is slow and hard to standardize - yet it is essential to prioritize repurposing opportunities and generate defensible rationale for follow-up.
1,000s of drugs screened automatically
Explore repurposing space at scale by systematically analyzing thousands of candidates per signature with standardized scoring and evidence gathering.
3× faster candidate prioritization
Move from manual landscape reviews to ranked shortlists with mechanistic justification and safety-aware KPIs in a repeatable workflow.
Defensible go/no-go rationale
Support decisions with traceable evidence and consistent KPIs (disease anchor, signature fit, safety) to align teams and de-risk downstream validation.
How it works
1
Ingest signature and disease context — provide signature data, disease context, and up/down regulation hypotheses to define what “reversal” should look like.
2
Run large-scale repurposing analysis — Biolevate screens thousands of repurposing candidates and gathers publicly available evidence for each drug (mechanism, targets, known biology).
3
Compute therapeutic potential KPIs — score candidates on disease anchoring (connectivity to the disease/signature), signature fit (ability to reverse phenotype at signature level), and safety (toxicity and risk signals).
4
Deliver ranked shortlists with justification — generate a table + report with biologically grounded justification of each drug’s expected impact on the signature, including mechanistic explanations and traceable sources.
Signature-level reversal focus: evaluates programmatic fit to the phenotype, not just target-level associations.
Mechanistic + safety balance: combines biological relevance with safety/toxicity signals to produce actionable, de-risked shortlists.